Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2026)
Vivos Therapeutics (VVOS) reported Return on Capital Employed of 315.56% for Q1 2026, down 18384.0% year-over-year from N/an in Q1 2025, and down 16.11% on a QoQ basis from 271.77% in Q4 2025.
Vivos Therapeutics (VVOS) has 6 years of Return on Capital Employed data on file, last reported at 315.56% in Q1 2026.
- Quarterly Return on Capital Employed fell 18384.0% year-over-year to 315.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 315.56% (down 18384.0% YoY) and the FY2025 annual result came in at 928.76%, down 78963.0% from the prior year.
- Return on Capital Employed declined to 315.56% in Q1 2026 per VVOS's latest filing, from 271.77% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 29.58% in Q1 2022 and bottomed at 534.7% in Q4 2023.
- The 5-year median for Return on Capital Employed is 187.94% (2024), against an average of 223.93%.
- The widest annual swing landed in 2023, when Return on Capital Employed plunged 32831 bps; it then soared 42663 bps in 2024.
- Tracing VVOS's Return on Capital Employed over 5 years: stood at 271.15% in 2022, then plunged by 97 bps to 534.7% in 2023, then soared by 80 bps to 108.07% in 2024, then sank by 151 bps to 271.77% in 2025, then retreated by 16 bps to 315.56% in 2026.
- Per Business Quant, the three latest VVOS Return on Capital Employed figures stand at 315.56% (Q1 2026), 271.77% (Q4 2025), and 88.7% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 7.62% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 11.57% |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -315.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -315.56% |
| Dec 31, 2025 | -271.77% |
| Sep 30, 2025 | -88.70% |
| Jun 30, 2025 | -116.37% |
| Mar 31, 2025 | -131.73% |
| Dec 31, 2024 | -108.07% |
| Sep 30, 2024 | -119.40% |
| Jun 30, 2024 | -187.94% |
| Mar 31, 2024 | -502.82% |
| Dec 31, 2023 | -534.70% |
| Sep 30, 2023 | -395.09% |
| Jun 30, 2023 | -300.55% |
| Mar 31, 2023 | -315.25% |
| Dec 31, 2022 | -271.15% |
| Sep 30, 2022 | -66.78% |
| Jun 30, 2022 | -51.28% |
| Mar 31, 2022 | -29.58% |
| Dec 31, 2021 | -14.27% |
| Sep 30, 2021 | -54.29% |
| Jun 30, 2021 | -62.78% |
| Mar 31, 2021 | -78.85% |